Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor-α in Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study.

Singh S, Dogra S, Shafiq N, Bhansali A, Malhotra S.

Int J Appl Basic Med Res. 2017 Jul-Sep;7(3):169-175. doi: 10.4103/ijabmr.IJABMR_330_16.

PMID:
28904916
2.

Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.

Furue M, Tsuji G, Chiba T, Kadono T.

Intern Med. 2017;56(13):1613-1619. doi: 10.2169/internalmedicine.56.8209. Epub 2017 Jul 1.

3.

Serum fatty acid profile in psoriasis and its comorbidity.

Myśliwiec H, Baran A, Harasim-Symbor E, Myśliwiec P, Milewska AJ, Chabowski A, Flisiak I.

Arch Dermatol Res. 2017 Jul;309(5):371-380. doi: 10.1007/s00403-017-1748-x. Epub 2017 Jun 5.

4.

Exploring the link between cadmium and psoriasis in a nationally representative sample.

Liaw FY, Chen WL, Kao TW, Chang YW, Huang CF.

Sci Rep. 2017 May 11;7(1):1723. doi: 10.1038/s41598-017-01827-9.

5.

Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.

Lerman JB, Joshi AA, Chaturvedi A, Aberra TM, Dey AK, Rodante JA, Salahuddin T, Chung JH, Rana A, Teague HL, Wu JJ, Playford MP, Lockshin BA, Chen MY, Sandfort V, Bluemke DA, Mehta NN.

Circulation. 2017 Jul 18;136(3):263-276. doi: 10.1161/CIRCULATIONAHA.116.026859. Epub 2017 May 8.

PMID:
28483812
6.

The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.

Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, Sierka D, Bourret JA, Evans TS, Gottlieb A.

Am Health Drug Benefits. 2016 Dec;9(9):504-513. Review.

7.

Psoriasis as a human model of disease to study inflammatory atherogenesis.

Harrington CL, Dey AK, Yunus R, Joshi AA, Mehta NN.

Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H867-H873. doi: 10.1152/ajpheart.00774.2016. Epub 2017 Mar 3. Review.

PMID:
28258057
8.

Diagnosis and underdiagnosis of comorbidities in psoriasis patients - need for a multidisciplinary approach.

Duarte GV, Oliveira MF, Follador I, Silva TS, Carvalho EM Filho.

An Bras Dermatol. 2016 Nov-Dec;91(6):743-747. doi: 10.1590/abd1806-4841.20164716.

9.

Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Wang Y, Golden JB, Fritz Y, Zhang X, Diaconu D, Camhi MI, Gao H, Dawes SM, Xing X, Ganesh SK, Gudjonsson JE, Simon DI, McCormick TS, Ward NL.

JCI Insight. 2016 Dec 8;1(20):e89384.

10.

Evaluation of inhomogeneities of repolarization in patients with psoriasis vulgaris.

Soylu K, İnci S, Aksan G, Nar G, Yüksel EP, Ocal HS, Çapraz M, Yüksel S, Şahin M.

Arch Med Sci. 2016 Dec 1;12(6):1225-1231. Epub 2016 Oct 24.

11.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E.

J Clin Aesthet Dermatol. 2016 Sep;9(9 Suppl 1):S5-S29. Epub 2016 Sep 1. No abstract available.

12.

GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.

Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, Krishnamoorthy P, Ng Q, Aridi TZ, Salahuddin T, Natarajan B, Lockshin BN, Ahlman MA, Chen MY, Rader DJ, Reilly MP, Remaley AT, Bluemke DA, Playford MP, Gelfand JM, Mehta NN.

Circ Res. 2016 Nov 11;119(11):1242-1253. doi: 10.1161/CIRCRESAHA.116.309637. Epub 2016 Sep 21.

PMID:
27654120
13.

Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances.

Oyinlola JO, Campbell J, Kousoulis AA.

BMC Health Serv Res. 2016 Jul 26;16:299. doi: 10.1186/s12913-016-1562-8.

14.

Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center.

Santilli S, Kast DR, Grozdev I, Cao L, Feig RL, Golden JB, Debanne SM, Gilkeson RC, Orringer CE, McCormick TS, Ward NL, Cooper KD, Korman NJ.

J Transl Med. 2016 Jul 22;14(1):217. doi: 10.1186/s12967-016-0947-0.

15.

Incidence, clinical manifestations and clipping of nail psoriasis in the dermatology center of the Hospital Universitário Evangélico de Curitiba.

Garbers LE, Slongo H, Fabricio LH, Schmitt JV, Bonalumi A Filho.

An Bras Dermatol. 2016 May-Jun;91(3):300-5. doi: 10.1590/abd1806-4841.20164296.

16.

Targeting vascular (endothelial) dysfunction.

Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T.

Br J Pharmacol. 2017 Jun;174(12):1591-1619. doi: 10.1111/bph.13517. Epub 2016 Jul 4. Review.

PMID:
27187006
17.
18.

Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.

Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, Viswanathan HN, Gelfand JM.

J Am Acad Dermatol. 2016 Jun;74(6):1057-1065.e4. doi: 10.1016/j.jaad.2016.01.048. Epub 2016 Mar 4.

19.

Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.

Shiba M, Kato T, Funasako M, Nakane E, Miyamoto S, Izumi T, Haruna T, Inoko M.

PLoS One. 2016 Feb 24;11(2):e0149316. doi: 10.1371/journal.pone.0149316. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158699.

20.

Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.

Lynch M, Ahern TB, Timoney I, Sweeney C, Kelly G, Hughes R, Tobin AM, O'Shea D, Kirby B.

Trials. 2016 Jan 15;17:29. doi: 10.1186/s13063-016-1157-z.

Supplemental Content

Support Center